Literature DB >> 29521545

Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Promising Medication for Chronic Obstructive Pulmonary Disease?

Ioannis E Vasileiadis1, Christos A Goudis2, Pinelopi T Giannakopoulou1, Tong Liu3.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a complex disorder that primarily affects the lungs and is characterized not only by local pulmonary, but also by systemic inflammation which promotes the development of extrapulmonary and cardiovascular co-morbidities. Angiotensin converting enzyme (ACE) inhibitors and ARBs (angiotensin receptor blockers) are widely used drugs in the treatment of cardiovascular diseases, with growing evidence suggesting potential benefits in COPD patients. The purpose of this review is to describe the correlation of renin-angiotensin system (RAS) with COPD pathophysiology and to present the latest data regarding the potential role of RAS blockers in COPD.

Entities:  

Keywords:  Angiotensin converting enzyme inhibitor; angiotensin receptor blocker; chronic obstructive pulmonary disease; renin-angiotensin system

Mesh：

Substances：

Year:  2018        PMID： 29521545     DOI： 10.1080/15412555.2018.1432034

Source DB:  PubMed          Journal:  COPD        ISSN： 1541-2563            Impact factor:   2.409


  7 in total

1.  Short Communication: A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study.

Authors:  David M MacDonald; Gary Collins; Chris H Wendt; Julian Wolfson; Russell P Tracy; Frank Rhame; Steven Deeks; Stacey A Rizza; Zelalem Temesgen; Caryn Morse; Angelike P Liappis; Irini Sereti; Jason V Baker; Ken M Kunisaki
Journal:  AIDS Res Hum Retroviruses       Date:  2021-04-30       Impact factor: 2.205

2.  β-Blocker Therapy and Risk of Chronic Obstructive Pulmonary Disease - A Danish Nationwide Study of 1·3 Million Individuals.

Authors:  Anne Orholm Nielsen; Lars Pedersen; Birgitte Fischer Sode; Morten Dahl
Journal:  EClinicalMedicine       Date:  2019-01-29

3.  Losartan does not inhibit cigarette smoke-induced lung inflammation in mice.

Authors:  M L Hepworth; S L Passey; H J Seow; R Vlahos
Journal:  Sci Rep       Date:  2019-10-21       Impact factor: 4.379

4.  Renin-angiotensin system antagonists and mortality due to pneumonia, influenza, and chronic lower respiratory disease in patients with hypertension.

Authors:  Heng-Xuan Cai; Chen-Chen Liang; Shan-Jie Wang; Jun-Chen Guo; Ye Wang; Bo Yu; Xue-Qin Gao; Shao-Hong Fang
Journal:  J Geriatr Cardiol       Date:  2022-07-28       Impact factor: 3.189

5.  RAS inhibition and COVID-19: more questions than answers?

Authors:  Mathieu Kerneis; Gilles Montalescot
Journal:  Lancet Respir Med       Date:  2021-06-11       Impact factor: 30.700

6.  Insertion/deletion polymorphism of angiotensin-converting enzyme and chronic obstructive pulmonary disease: A case-control study on north Indian population.

Authors:  Nikhil Kirtipal; Hitender Thakur; Ranbir Chander Sobti
Journal:  Mol Biol Res Commun       Date:  2019-12

7.  Diagnosing sarcopenia: Functional perspectives and a new algorithm from the ISarcoPRM.

Authors:  Murat Kara; Bayram Kaymak; Walter Frontera; Ayşe Merve Ata; Vincenzo Ricci; Timur Ekiz; Ke-Vin Chang; Der-Sheng Han; Xanthi Michail; Michael Quittan; Jae-Young Lim; Jonathan F Bean; Franco Franchignoni; Levent Özçakar
Journal:  J Rehabil Med       Date:  2021-06-21       Impact factor: 2.912
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.